ProCE Banner Activity

Understanding BTK Inhibitor Resistance in CLL

Slideset

Review key data surrounding BTK inhibitor resistance in CLL, including optimal testing and treatment sequencing to overcome resistance to prior therapy. 

Released: October 01, 2024

Expiration: September 30, 2025

Share

Faculty

Matthew S Davids

Matthew S Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Lindsey Roeker

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca